Sandoz Fills Pipeline Gap With EirGenix Trastuzumab Deal
Sandoz has acquired global commercial rights to EirGenix’ Phase III trastuzumab candidate, filling a gap in the Novartis division’s biosimilars pipeline.
You may also be interested in...
Sandoz and EirGenix have followed their US filing for a biosimilar rival to Herceptin with a European filing for the EG12014 trastuzumab candidate.
Sandoz has filed the proposed trastuzumab biosimilar developed by partner EirGenix with the US FDA. If approved, the product will have to compete in an already busy market for Herceptin biosimilars.
Sandoz has plugged another gap in its off-patent oncology pipeline, from which the company has rolled-out four marketed oncology biosimilars, by bringing in Bio-Thera Solutions’ BAT1706 proposed biosimilar to Avastin, including in the US and Europe.